1288 results about "Sepsis" patented technology

The invention relates to the technical field of disease risk assessment, in particular to a prediction support system for a high risk level of a sepsis patient. According to the abnormal degree of the physiological data in the abnormal time period of each category and the time interval between the abnormal time period and the adjacent abnormal time period, the importance degree of each category is obtained; selecting a feature category and a target time period based on the importance, and obtaining the severity of the target time period according to the importance difference between all categories in the target time period and the feature category and the number of categories with abnormal physiological data in the target time period; and acquiring a high risk value according to the change trend and the time interval of the severity of the target time period and the adjacent target time period, and adjusting and analyzing all types of physiological data in the time period by using the high risk value so as to predict the high risk of sepsis of the to-be-detected patient. According to the method, the difference of the physiological data in the time period in which the abnormal expression has the difference is dynamically expanded through the high-risk value, so that the accuracy of predicting the high-risk condition of sepsis is improved.

The invention relates to the technical field of intelligent medical treatment, and discloses an AI-based severe patient sepsis early warning method and system. According to the method, a multi-organ interaction mechanism is deeply analyzed by dynamically constructing an organ-level causal network, and early-stage accurate early warning of sepsis is realized: high-frequency physiological waveforms, asynchronous laboratory indexes and treatment intervention data are fused, and the capture ability of microcirculation failure and autonomic nerve decline is improved; the early warning threshold value is dynamically adjusted based on the treatment coverage degree, and the delay and false alarm defects of a fixed threshold value mechanism are effectively overcome; a pathogen targeted therapy map and an organ function support scheme are automatically generated by a graded triggered clinical action chain, and the clinical decision response time is shortened; according to the method, the risk of missed diagnosis is reduced while the early warning sensitivity is improved, and an earlier and more reliable intervention window is provided for critical patients.

The invention provides a metal polyphenol nanoparticle, a preparation method thereof and an application of the metal polyphenol nanoparticle in preparation of a medicine for treating acute lung injury, the metal polyphenol nanoparticle is formed by self-assembly of metal ions and polyphenol, the metal ions are selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >, and the polyphenol is selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >. The polyphenol is selected from epigallocatechin gallate (EGCG), caffeic acid (CA), chlorogenic acid (CGA), gallic acid (GA) and luteolin (LUT). The metal polyphenol nanoparticles are used for preparing a medicine for treating acute lung injury induced by sepsis, pneumonia, serious trauma or inhalation injury, and the medicine further comprises a pharmaceutically acceptable carrier. The metal polyphenol nanoparticles provided by the invention are simple in preparation process and high in biological safety, polyphenol and metal ions synergistically enhance the anti-inflammatory and antioxidant activity, and the metal polyphenol nanoparticles are superior to the single use of polyphenol or metal ions.

The invention relates to a causal anti-fact sepsis auxiliary decision-making method of Transform, and belongs to the field of medical big data. The method is realized by a causal anti-fact sepsis auxiliary decision-making model based on Transform. The causal anti-fact sepsis auxiliary decision-making model based on the Transform is formed by connecting an action generation network with a causal Transform network in series. The method comprises the following steps: S1, preprocessing input data; s2, establishing a causal anti-fact sepsis auxiliary decision-making model based on a Transform; s3, predicting the state of the patient at the next moment by using a multi-layer decoder; s4, using the action generation network to predict an intervention action at the next moment; s5, updating the state of a multi-layer decoder of the causal Transform network; and S6, predicting the risk of sepsis of the patient, and carrying out interpretable analysis. According to the method, accurate selection and recommendation of intervention actions can be realized, accurate feature expression is predicted and generated, judgment of an intervention effect is assisted, and interpretable analysis is realized.

The invention relates to the technical field of deterioration prediction, in particular to a sepsis deterioration prediction method and system based on traditional Chinese medicine big data, and the method comprises the following steps: based on a sepsis patient, extracting the traditional Chinese medicine constitution and physiological index data of the patient, comparing the data with normal constitution data and standard physiological indexes provided by the traditional Chinese medicine big data, and according to the data deviation, determining the sepsis deterioration of the patient. And evaluating the physique state of the patient to obtain a patient physique evaluation result. According to the method, the physical state and the disease development risk of the patient can be accurately evaluated by combining the analysis of the traditional Chinese medicine physique and the physical indexes and utilizing the comprehensive comparative analysis of the physical data such as the pulse condition and the tongue condition of the traditional Chinese medicine and the traditional physical indexes, and the high-risk patient can be identified by analyzing the fluctuation of the data and the change of the time sequence. The method effectively predicts the instability and deterioration probability of the illness state, carries out dynamic evaluation according to the physical condition of the patient and the severity of sepsis, provides data support for treatment, and enhances the accuracy and timeliness of medical prediction.

The invention discloses a monoclonal antibody for resisting staphylococcus aureus iron ion regulatory surface determinant B protein and application of the monoclonal antibody. Amino acid of a structural domain recognized by the monoclonal antibody is shown as SEQ ID NO.1. The monoclonal antibody is generated by culturing a host cell of an expression vector, the generated monoclonal antibody is secreted into supernate, and the supernate is secreted into the staphylococcus aureus iron ion regulatory surface determinant B protein to obtain the staphylococcus aureus iron ion regulatory surface determinant B. The staphylococcus aureus iron ion regulatory surface determinant B protein. Purifying through a chromatography technology; the obtained antibody can be used for treating septicopyemia caused by staphylococcus aureus / MRSA infection, and has important significance in preventing and treating staphylococcus aureus infection.

The invention discloses an ICU sepsis two-stage early prediction method and device and a storage medium, and the method comprises the steps: continuously collecting a clinical data set after a patient enters an ICU, and carrying out the feature extraction, and obtaining a prediction feature vector; based on the predicted feature vector corresponding to the clinical data set at the current observation moment, determining whether the patient is a non-sepsis sample by using a preset classification model; and if the patient is not determined as a non-sepsis sample by the classification model, predicting whether the patient has a sepsis infection risk in a future preset time period or not by using a preset prediction model according to the current observation moment and the prediction feature vector corresponding to the clinical data set in the previous set time. According to the application, a two-stage mode is adopted, patients are subjected to layered screening, and samples which do not obviously belong to sepsis are excluded; and for the samples which are not excluded, more accurate sepsis risk prediction is carried out by using the prediction model in combination with the prediction feature vectors corresponding to the clinical data of the plurality of time periods, so that the prediction accuracy is improved.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and / or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

The invention relates to the field of acute lung injury caused by sepsis, in particular to application of lactobacillus rhamnosus exosome in preparation of medicine for treating and / or preventing acute lung injury caused by sepsis of subjects, and the acute lung injury caused by sepsis is acute complication of sepsis. The sepsis is caused by bacterial infection, and the particle size of the lactobacillus rhamnosus exosome ranges from 50 nm to 120 nm. The lactobacillus rhamnosus exosome provided by the invention can prevent and / or timely and effectively prevent the development of the disease course of a subject at the initial stage of sepsis acute lung injury, and finally, the treatment success rate of the subject is increased, and the prognosis of the subject is improved.

The invention specifically relates to a clinical deterioration risk prediction and early warning system and method based on machine learning, and relates to the technical field of medical artificial intelligence and clinical informatics, and the method comprises the steps: obtaining multi-dimensional time series data in real time; constructing a dynamic feature engineering vector; machine learning risk prediction; judging a risk threshold value and triggering early warning; and interpretation and suggestion generation driven by the large language model. According to the method, multi-dimensional time sequence data is continuously acquired in real time, multi-sliding window statistical features and standardized clinical deterioration scores are extracted in combination with dynamic feature engineering, and accurate quantitative risk prediction of multiple disease deterioration types such as sepsis and respiratory failure is realized by means of machine learning models which are specifically trained by XGBoost, LSTM and the like. The problem that traditional early warning depends on manual judgment and is high in hysteresis is effectively solved; medical staff can be helped to quickly grasp the core inducement of disease deterioration, and a standardized and landing action scheme is provided.

The invention discloses a sepsis-related acute kidney injury intelligent prediction system and a hierarchical management method, and the system comprises a multi-modal data collection module which synchronously collects an ultrasound contrast video, a urine biomarker and hemodynamic parameters in real time; the spatio-temporal feature extraction module is used for extracting multi-modal spatio-temporal features; modeling a dynamic interaction effect of heart and kidney nodes through a dynamic organ interaction graph network; the self-supervised pre-training module is used for improving the generalization of the model through comparative learning; the dynamic risk prediction module outputs a risk probability curve in the next 24 hours; the hierarchical decision management module is used for generating personalized strategies of liquid management, vasoactive drug adjustment and kidney replacement treatment opportunity; and the interpretability module is used for analyzing the key early warning characteristics based on the SHAP value. According to the method, the problems of deficiency of organ interaction modeling, poor generalization of small samples, stiffness of static decision and the like are solved, and the early warning and precise treatment capabilities of the sepsis-related kidney injury are remarkably improved.

The invention discloses a method for identifying key mitochondrial autophagy and ferroptosis genes in sepsis-induced ARDS and an immunoregulation mechanism of the key mitochondrial autophagy and ferroptosis genes. The method comprises the following steps: screening differential expression genes DEGs related to the sepsis-induced ARDS from a GEO gene expression database; and screening the DEGs by using LASSO and SVM + RFE, and identifying 12 key DEGs. The diagnostic potential of the genes in sepsis-induced ARDS is verified through an ROC curve, and the effect of the genes in immune response is disclosed through gene enrichment analysis and immune infiltration analysis. According to the invention, a key gene FTH1 is identified, a miRNA gene [miR-224-5p] targeting the FTH1 and a pathologic process in which the miRNA gene [miR-224-5p] participates in regulation and control of sepsis-induced ARDS are found, and a close relationship between the FTH1 and E3 ubiquitin ligase SMURF1 is found.

The invention discloses an ICU patient sepsis occurrence risk prediction method and system. The method comprises the following steps: collecting clinical time sequence data of an ICU patient; performing information extraction processing on the clinical time sequence data of the ICU patient based on a structured query language technology and a semantic analysis model; constructing a data set; constructing eight dichotomy machine learning models, and selecting the dichotomy machine learning model with the highest AUROC value as a sepsis prediction model; screening effective features; a Platt Scaling algorithm and the calibration set are adopted to carry out calibration processing on the sepsis prediction model, and a calibrated sepsis prediction model is obtained; and acquiring real-time clinical time sequence data of the target ICU patient, preprocessing the real-time clinical time sequence data of the target ICU patient, inputting the preprocessed real-time clinical time sequence data into the calibrated sepsis prediction model, and outputting and displaying a sepsis occurrence risk prediction result. According to the method, human intervention is not needed, the sepsis occurrence risk of the ICU patient can be monitored in real time, and important support is provided for early warning of sepsis.

The invention relates to application of 4-GBA in preparation of a medicine for improving infection endurance capacity of a sepsis patient, 4-GBA is used for treating mice infected with sepsis, compared with control mice, the survival rate of the mice treated by the 4-GBA is far larger than that of the control mice, and experiments prove that the 4-GBA has a protection effect on sepsis infection. The mechanism of 4-GBA for improving infection endurance capacity of sepsis patients is researched, and after 4-GBA treatment, the content of liver and kidney functional markers in peripheral blood serum of mice infected with sepsis is remarkably reduced, the content of DAMPs (injury related molecular patterns) related molecules in peripheral blood serum of mice infected with sepsis is remarkably reduced, and the application of 4-GBA in the treatment of the mice infected with sepsis in the treatment of the infection endurance capacity of the patients infected with sepsis in the treatment of the infection endurance capacity of the patients infected with sepsis in the treatment of the patients infected with sepsis in the treatment of the patients infected with sepsis. And the product does not have in-vivo and in-vitro sterilization functions and body immune regulation functions. The result shows that 4-GBA can improve the infection endurance capacity of the sepsis patient, and provides a new direction and a new drug for treatment of the sepsis patient.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention provides application of piperidine acid in preparation of a medicine for treating sepsis, and relates to the technical field of new application of medicines. The invention finds that the piperidine acid can obviously improve the symptom of sepsis and has no obvious side effect. Therefore, the piperidine acid can be used for developing a novel medicine for treating sepsis, and has wide medical prospects and economic values.

The invention discloses a sepsis cardiomyopathy cardiac function data analysis detector and a detection method, and relates to the technical field of cardiomyopathy cardiac function detection.The sepsis cardiomyopathy cardiac function data analysis detector comprises a monitoring mechanism, the monitoring mechanism comprises a cover plate, an electrocardiograph monitor is arranged behind the cover plate, and two elastic bands are fixedly connected to the back face of the cover plate; a data collection mechanism is arranged outside the cover plate; according to the sepsis cardiomyopathy cardiac function data analysis detector and the detection method, various cardiac function data, such as electrocardiogram, heart rate, maximum oxygen uptake, blood oxygen level, R-R interval, blood pressure and blood flow conditions, of a sepsis patient can be detected more conveniently and quickly; according to the method, independent examination can be carried out without using various examination devices, so that the diagnosis time of the patient is greatly shortened, medical personnel can quickly obtain cardiac function data of the sepsis patient, and a doctor can timely find whether the sepsis patient develops into a cardiomyopathy symptom or not.

The invention discloses a silicon shell protected magnetic quantum dot nanoprobe, a preparation method, a kit and application. The nanoprobe comprises a nanomaterial and a specific antibody, the nanometer material is of a core-shell structure, and the outer surface of a core is sequentially coated with an interlayer and a protective shell layer outwards. The interlayer comprises a multi-layer laminated structure formed by alternately arranging a plurality of layers of positive electricity interlayers and negative electricity interlayers; the positive electric interlayer is polyethyleneimine, the negative electric interlayer is quantum dots, the quantum dots are CdSe / ZnS or carbon quantum dots, amino groups on the surface of the shell layer and a dialkynyl polyethylene ethanol solution are subjected to general coupling of specific antibodies in a click chemistry mode by taking diyne molecules as connecting arms. The magnetic nanoprobe with the core-shell structure not only has strong magnetic responsiveness and a high fluorescence signal, but also can adapt to a complex environment, after the magnetic nanoprobe is integrated with an immunochromatography test strip, to-be-detected targets including pathogenic bacteria and inflammatory markers can be rapidly captured in a whole blood sample at the same time, and the magnetic nanoprobe has huge application potential in early diagnosis of sepsis.

The present disclosure relates to methods of treating sepsis or septic conditions in patients who have heightened LIGHT, IL-18 levels or biomarkers listed herein which can be treated with molecules that inhibit biomarker activity.

The invention provides a method for processing gastrointestinal ultrasonic data of a sepsis patient. The method comprises the following steps: acquiring a to-be-detected ultrasonic image, determining a gastrointestinal contour according to the to-be-detected ultrasonic image, determining a feature point set according to the gastrointestinal contour, determining a gastrointestinal wall thickness set according to the feature point set and the gastrointestinal contour, and finally determining the gastrointestinal wall thickness according to the gastrointestinal wall thickness set. And determining a target point set from the feature point set according to the gastrointestinal wall thickness set, and identifying each target point in the target point set in the to-be-detected ultrasonic image to generate an identified ultrasonic image so as to realize automatic identification and labeling of the thickened position of the gastrointestinal wall in the gastrointestinal ultrasonic image of the sepsis patient. Therefore, a doctor can quickly and accurately position possibly existing inflammation or other pathological changes, and the diagnosis efficiency and accuracy are improved.

The invention provides a sepsis early-stage risk prediction system, and relates to the technical field of sepsis risk prediction, the sepsis early-stage risk prediction system comprises a data acquisition module, a data preprocessing module, a risk assessment module, a result display module and a data management module, and the data acquisition module is used for acquiring vital signs, laboratory data and medical record data through vital sign acquisition, laboratory data acquisition and medical record data acquisition; the data is collected from three aspects; the data preprocessing module can process the data and find features related to the early stage of sepsis from the collected data; the risk assessment module firstly scores, and determines whether machine prediction or expert prediction is performed according to the score level; and the result display module displays the evaluation result through visual display, and generates a report according to patient demands. The system has the advantages that multi-dimensional data such as vital signs of a patient, laboratory examination and electronic medical records are comprehensively collected through the data acquisition module, data islands are broken, and a rich information basis is provided for accurate prediction.

The invention discloses a macrophage-targeting inhalable nano material, a preparation method thereof and application of the inhalable nano material in treatment of sepsis myocarditis, and belongs to the technical field of medicines. The nano-material is a nano-liposome, the nano-liposome comprises a mannose modified nano-liposome microsphere, and the mannose modified nano-liposome microsphere comprises a liposome skeleton shell layer, a drug and a targeting layer; the liposome skeleton shell layer comprises soybean lecithin and cholesterol; the medicine comprises quercetin and TPPU (Thermoplastic Polyurethane); and the targeting layer is formed by connecting mannose modified DSPE-PEG2000 to the outer surface of the liposome skeleton shell layer. The nano material can accurately target macrophages at a cardiac inflammation part, has a multi-target-point synergistic effect, is more convenient and faster in administration, remarkably improves the safety and comprehensively improves the treatment effect.

The invention belongs to the field of biological medicines, and relates to a drug-loaded nano-vesicle as well as a preparation method and application thereof. The drug-loaded nano-vesicle comprises a vesicle core and a drug-loaded nano-vesicle, wherein the vesicle core comprises siRNA (small interfering Ribonucleic Acid) capable of specifically targeting and silencing an NR1D1 gene; the vesicle membrane is formed by fusing an erythrocyte membrane, a macrophage membrane, cardiolipin, cholesterol and lecithin. The drug-loaded nano-vesicle can specifically target macrophages in a sepsis immunosuppression stage, has an intracellular response release function, recovers BMAL1 and IGF2BP2-ATP6V1B2 / ATP6V0c axis functions by inhibiting NR1D1 expression, reconstructs a macrophage phagocytosis function and lysosome-dependent bacterium removal capability, and can be used for preparing a drug-loaded nano-vesicle with a specific targeting function. The survival rate of sepsis immunosuppression model animals is obviously improved; and the bacterial load is reduced. Compared with a traditional electroporation method, the preparation method disclosed by the invention has the advantage that the encapsulation efficiency of siRNA is remarkably improved.

The invention provides a method for treating COVID-19 patients. Therapeutic antibodies of certain types of antibodies to COVID-19 are identified early by targeted diagnostic testing can be given to other COVID-19 patients to enhance their recovery. This invention also identifies bacterial pathogens, particularly those that are resistant to antibiotics, faster. Data from deep RNA sequencing of human blood is used to create a faster diagnostic test for infections and associated antimicrobial resistance. This invention thus also allows for appropriate antibiotic treatment at an earlier time point. The invention further provides improvements to RNA sequencing that can make RNA sequencing useful for diagnostic and therapeutic methods of treating sepsis. RNA sequencing can identify bacterial pathogens directly from the blood of patients with those infections.

The invention provides a biomarker for sepsis encephalopathy and application of the biomarker. The biomarker is selected from any one or a combination of more than two of 5-HTP, 5-HIAA or 5-HIAA / 5-HT according to a ratio of 5-HTP to 5-HIAA to 5-HT. The biomarker has the advantages of high sensitivity and high precision, and development and utilization of the key biomarker have important value in precise diagnosis, prognosis, subsequent treatment and drug screening of sepsis encephalopathy.

The present invention discloses a method for the preparation and application of modified extracellular vesicles specifically targeted to the kidneys. These modified extracellular vesicles are derived from fibroblastic reticular cells in the mesentery tissue and express anti-inflammatory proteins after being modified with anchor peptides. By combining the extracellular vesicles secreted from fibroblastic reticular cells in the mesentery tissue with anchor peptides, the present invention ensures the effective targeting of the exosomes to the kidneys. Additionally, through genetic engineering of fibroblastic reticular cells, the exosomes secreted by these cells can carry the target molecule, anti-inflammatory protein CD5L, achieving precise targeted therapy for the kidneys. This innovative treatment strategy holds promising potential for the treatment of sepsis-associated acute kidney injury, bringing positive impacts to patients' health.

The present disclosure provides methods of treating or preventing inflammatory bowel disease or sepsis in a subject by inhibiting SUMOylation in the subject.

A computer-implemented method comprising: performing a prediction process comprising: based on input data comprising values of physiological measurement variables of a patient over a time period, computing first correlations in the input data, the computing comprising computing short range temporal correlations between values of physiological measurement variables at consecutive time steps using an attention-based mechanism and computing spatial correlations between values of different physiological measurement variables at a same time step using a self-attention mechanism; generating first updated node embeddings based on the input data and the first correlations, each node corresponding to a physiological measurement variable at a time step; using a recurrent neural network, RNN, updating the first updated node embeddings based on second correlations between the first updated node embeddings to generate temporally updated embeddings; and based on the temporally updated embeddings and using a neural network, NN, generating a prediction whether the patient will have sepsis.

The invention discloses an antibacterial peptide P1 and medical application thereof in treating sepsis. The amino acid sequence of the antibacterial peptide P1 is as shown in SEQ ID NO. 1. The antibacterial peptide P1 provided by the invention has a good treatment effect on a sepsis mouse CLP model. The antibacterial peptide P1 can play a good bactericidal effect by directly destroying cell walls and cell membranes of staphylococcus aureus; the antibacterial peptide P1 also has bacterial capture ability and immunomodulatory activity, and can relieve survival rate reduction induced by sepsis, liver and lung injury caused by sepsis, liver and lung injury caused by sepsis, and organ bacterial infection caused by sepsis. Cell walls and cell membranes of staphylococcus aureus are directly destroyed, and a network structure is formed in a hydrophobic environment to capture bacteria and promote phagocytosis of immune cells. The compound is a good novel antibiotic substitute product, and can be used for preparing drugs for treating sepsis.

The invention discloses application of Eucommia lignan in preparation of drugs for preventing and treating sepsis in the technical field of medicines. According to the scheme, the effects of the eucommia ulmoides lignan on the aspects of relieving sepsis inflammatory response, regulating cell phenotype and related protein gene expression, relieving neuron damage and the like are fully verified from the cell and animal levels, and the application value of the eucommia ulmoides lignan in preparation of the medicine for preventing and treating sepsis is proved.